Key Points BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites. A new drug candidate similar to BioAge's BGE-102 recently produced encouraging clinical trial results. 10 stocks we like better than BioAge Labs › Most of 2025 has been disappointing for BioAge Labs (NASDAQ: BIOA) shareholders, but things are looking up. During the week that ended Oct. 25, shares o ...